MedTrace Logo

Study to Evaluate the Adjunctive Effect of CreNeuroS™ CNS Fish Oil Plus Softgels in Patients With Major Depressive Disorder Receiving Escitalopram.

NCT07645807 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-06-16

No results posted yet for this study

Summary

To evaluate the efficacy of adjunctive CreNeuroSTM CNS Fish Oil Plus Softgels in patients with Major Depressive Disorder receiving escitalopram.

Conditions

  • Adjunct in the Treatment of Depressive Disorder

Interventions

COMBINATION_PRODUCT

1. Escitalopram (as escitalopram oxalate) tablet 2. CreNeuroSTM CNS Fish Oil Plus Softgels

1\. Escitalopram (as escitalopram oxalate) tablet 2. CreNeuroSTM CNS Fish Oil Plus Softgels.

COMBINATION_PRODUCT

1. Escitalopram (as escitalopram oxalate) tablet 2. Placebo softgels

1\. Escitalopram (as escitalopram oxalate) tablet and 2. Placebo softgels

Sponsors & Collaborators

  • Vivotech Research Lab Pvt Ltd

    collaborator UNKNOWN

  • Sichuan Credit Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-11
Primary Completion
2027-01-31
Completion
2027-01-31

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07645807 on ClinicalTrials.gov